# Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT01281150** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 22 (actual)

## Conditions studied

- Adult Solid Neoplasm
- Estrogen Receptor Negative
- Estrogen Receptor Positive
- HER2/Neu Negative
- Male Breast Carcinoma
- Progesterone Receptor Negative
- Recurrent Breast Carcinoma
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer
- Triple-Negative Breast Carcinoma

## Interventions

- **DRUG:** Carboplatin
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **OTHER:** Pharmacological Study
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT01281150
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2015-04
- **Final completion:** —
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2015-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01281150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01281150, "Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01281150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*